Background About 70% to 80% of adults with cancer experience chemotherapy‐induced
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …

Uncontrolled chemotherapy‐induced nausea and vomiting can reduce patients' quality of
life and may result in premature discontinuation of chemotherapy. Although nausea and …

Ovarian cancer is among the leading cause of cancer-related deaths in females. In this
study, we demonstrated that miR-595 expression was downregulated in the ovarian cancer …

Introduction: Chemotherapy induced nausea and vomiting (CINV) are major side effects of
chemotherapy and a great burden to patients' quality of life. Serotonin and substance P are …

A substantial proportion of cancer patients experience chemotherapy-induced nausea and
vomiting (CINV) despite the use of antiemetic drugs. Prevalent genetic polymorphisms …

Purpose Chemotherapy-induced nausea and vomiting (CINV) is common among cancer
patients. Early identification of patients at risk for CINV may help to personalize anti-emetic …

Purpose We aim to investigate the correlation between gene polymorphisms and cisplatin
chemotherapy-induced nausea and vomiting (CINV), which was prevented by olanzapine or …

The clinical application of Pharmacogenomics (PGx) has improved patient safety. However,
comprehensive PGx testing has not been widely adopted in clinical practice, and significant …

The occurrence and severity of chemotherapy-induced nausea and vomiting (CINV) are
influenced by many factors; this includes therapeutic factors, such as the dose …

Background We conducted an economic assessment using test data from the phase III
TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist …